



## EMPLOYEE SHARE PLAN VESTING CONDITIONS MET

**SYDNEY, 21 May 2015:** The Board of Actinogen Limited (Actinogen Medical, ASX: ACW), an Australian biotechnology company focused on the development of novel treatments for Alzheimer’s disease and other major age-related neurodegenerative disorders, wishes to advise that the following vesting condition has been met on Employee Share Plan shares issued to Dr Jason Loveridge:

Tranche	Number of Shares	Vesting Condition
Class B	3,000,000	On funding of the Phase 2 proof of concept study.

## ENDS

### Actinogen Medical

Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: [bill.ketelbey@actinogen.com.au](mailto:bill.ketelbey@actinogen.com.au)

 [@BillKetelbey](https://twitter.com/BillKetelbey)

### About Actinogen Medical

Actinogen Medical is focused on the treatment of Alzheimer’s disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious condition of Alzheimer’s dementia. It is developing a novel drug to treat the condition and other age-related neurodegenerative diseases. The lead candidate drug Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and amyloid plaques – hallmarks of Alzheimer’s disease. The Company is currently undertaking a second Phase I multiple ascending dose trial in healthy volunteers with results in mid-2015 and plans to undertake a Phase II study in 2016.